2/2
09:17 am
nxl
Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation [Yahoo! Finance]
Low
Report
Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation [Yahoo! Finance]
2/2
08:45 am
nxl
Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation
Medium
Report
Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation
1/23
05:33 pm
nxl
Nexalin Technology receives Nasdaq bid price deficiency notice [Seeking Alpha]
Medium
Report
Nexalin Technology receives Nasdaq bid price deficiency notice [Seeking Alpha]
1/23
05:15 pm
nxl
Nexalin Technology Receives Nasdaq Listing Status Notification
Low
Report
Nexalin Technology Receives Nasdaq Listing Status Notification
1/14
09:00 am
nxl
Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD
High
Report
Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD
12/3
08:00 am
nxl
Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program
Low
Report
Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program
12/2
08:00 am
nxl
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4
Medium
Report
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4
11/22
02:11 am
nxl
Nexalin Technology (NASDAQ:NXL) was downgraded by analysts at
Wall Street
Medium
Report
Nexalin Technology (NASDAQ:NXL) was downgraded by analysts at
Wall Street
11/22
02:11 am
nxl
Nexalin Technology (NASDAQ:NXL) was downgraded by analysts at
Wall Street
Medium
Report
Nexalin Technology (NASDAQ:NXL) was downgraded by analysts at
Wall Street
11/18
01:18 pm
nxl
Nexalin Technology (NASDAQ:NXL) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Nexalin Technology (NASDAQ:NXL) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/18
09:00 am
nxl
Nexalin’s 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity
Medium
Report
Nexalin’s 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity
11/13
10:27 am
nxl
Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel [Yahoo! Finance]
Medium
Report
Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel [Yahoo! Finance]
11/13
09:15 am
nxl
Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel
Medium
Report
Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel
11/12
01:27 pm
nxl
Nexalin Technology (NASDAQ:NXL) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Nexalin Technology (NASDAQ:NXL) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/7
01:14 am
nxl
Nexalin Technology (NASDAQ:NXL) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Nexalin Technology (NASDAQ:NXL) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/5
08:30 am
nxl
Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia
High
Report
Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia